Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126290751 | 12629075 | 1 | I | 20160801 | 20160808 | 20160808 | EXP | US-AMGEN-USASP2016100166 | AMGEN | 82.00 | YR | E | M | Y | 0.00000 | 20160808 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126290751 | 12629075 | 1 | PS | EPOGEN | ERYTHROPOIETIN | 1 | Subcutaneous | 60,000 UNITS, ONCE | U | 103234 | UNKNOWN FORMULATION | ||||||||
| 126290751 | 12629075 | 2 | SS | denosumab | DENOSUMAB | 1 | Unknown | UNK | U | 0 | UNKNOWN FORMULATION | ||||||||
| 126290751 | 12629075 | 3 | C | TORISEL | TEMSIROLIMUS | 1 | UNK | 0 | |||||||||||
| 126290751 | 12629075 | 4 | C | CHERATUSSIN AC | CODEINE PHOSPHATEGUAIFENESIN | 1 | Oral | 1-2 TSP (OF 100-10 MG/5ML) SYRUP, Q4 HOURS | 0 | ||||||||||
| 126290751 | 12629075 | 5 | C | HYDROCODONE/ACETAMINOPHEN | ACETAMINOPHENHYDROCODONE | 1 | Oral | 1-2 (10-325 MG), Q6 HOURS PRN | 0 | TABLET | QID | ||||||||
| 126290751 | 12629075 | 6 | C | PAXIL | PAROXETINE HYDROCHLORIDE | 1 | Oral | 20 MG, DAILY | 0 | 20 | MG | QD | |||||||
| 126290751 | 12629075 | 7 | C | PROCHLORPERAZINE MALEATE. | PROCHLORPERAZINE MALEATE | 1 | Oral | 10 MG, Q6 HOURS PRN | 0 | 10 | MG | TABLET | QID | ||||||
| 126290751 | 12629075 | 8 | C | ALPRAZOLAM. | ALPRAZOLAM | 1 | Oral | 0.5 MG, AT BED TIME | 0 | .5 | MG | TABLET | |||||||
| 126290751 | 12629075 | 9 | C | ALBUTEROL SULFATE. | ALBUTEROL SULFATE | 1 | UNK, INHALATION FOUR TIMES A DAY PRN | 0 | |||||||||||
| 126290751 | 12629075 | 10 | C | ATENOLOL. | ATENOLOL | 1 | Oral | 25 MG, DAILY | 0 | 25 | MG | TABLET | QD | ||||||
| 126290751 | 12629075 | 11 | C | COLACE | DOCUSATE SODIUM | 1 | Oral | 100 MG, PRN | 0 | 100 | MG | CAPSULE | |||||||
| 126290751 | 12629075 | 12 | C | DOXAZOSIN MESYLATE. | DOXAZOSIN MESYLATE | 1 | Oral | 8 MG, DAILY | 0 | 8 | MG | TABLET | QD | ||||||
| 126290751 | 12629075 | 13 | C | FERROUS SULFATE. | FERROUS SULFATE | 1 | Oral | 325 MG, DAILY | 0 | 325 | MG | TABLET | QD | ||||||
| 126290751 | 12629075 | 14 | C | CALCIUM 600 + D3 PLUS MINERALS | 2 | Oral | 600-800 MG, BID | 0 | CHEWABLE TABLET | BID | |||||||||
| 126290751 | 12629075 | 15 | C | LASIX | FUROSEMIDE | 1 | Oral | 20 MG, DAILY | 0 | 20 | MG | TABLET | QD | ||||||
| 126290751 | 12629075 | 16 | C | LEVEMIR | INSULIN DETEMIR | 1 | Subcutaneous | 12 UNITS (OF 100 UNITS/ML), BED TIME | 0 | ||||||||||
| 126290751 | 12629075 | 17 | C | LORATADINE. | LORATADINE | 1 | Oral | 10 MG, DAILY | 0 | 10 | MG | TABLET | QD | ||||||
| 126290751 | 12629075 | 18 | C | LOSARTAN POTASSIUM. | LOSARTAN POTASSIUM | 1 | Oral | 25 MG, DAILY | 0 | 25 | MG | TABLET | QD | ||||||
| 126290751 | 12629075 | 19 | C | MIRALAX | POLYETHYLENE GLYCOL 3350 | 1 | Oral | 17 G PACK, DAILY | 0 | QD | |||||||||
| 126290751 | 12629075 | 20 | C | MONTELUKAST SODIUM. | MONTELUKAST SODIUM | 1 | Oral | 10 MG, DAILY | 0 | 10 | MG | TABLET | QD | ||||||
| 126290751 | 12629075 | 21 | C | NOVOLOG | INSULIN ASPART | 1 | Subcutaneous | UNK UNK, FOUR TIMES A DAY PRN | 0 | QID | |||||||||
| 126290751 | 12629075 | 22 | C | POTASSIUM CHLORIDE. | POTASSIUM CHLORIDE | 1 | Oral | 10 MEQ, DAILY | 0 | 10 | MEQ | TABLET | QD | ||||||
| 126290751 | 12629075 | 23 | C | PRAVASTATIN SODIUM. | PRAVASTATIN SODIUM | 1 | Oral | 20 MG, AT BED TIME | 0 | 20 | MG | TABLET | |||||||
| 126290751 | 12629075 | 24 | C | TESSALON | BENZONATATE | 1 | Oral | 100 MG, TID PRN | 0 | 100 | MG | CAPSULE | TID | ||||||
| 126290751 | 12629075 | 25 | C | TYLENOL | ACETAMINOPHEN | 1 | Oral | 650 MG, PRN | 0 | 650 | MG | TABLET | |||||||
| 126290751 | 12629075 | 26 | C | VITAMIN D | CHOLECALCIFEROL | 1 | Oral | 1000 UNIT, DAILY | 0 | CAPSULE | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126290751 | 12629075 | 1 | Nephrogenic anaemia |
| 126290751 | 12629075 | 2 | Product used for unknown indication |
| 126290751 | 12629075 | 3 | Renal cancer metastatic |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126290751 | 12629075 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126290751 | 12629075 | Anorectal disorder | |
| 126290751 | 12629075 | Arthralgia | |
| 126290751 | 12629075 | Back pain | |
| 126290751 | 12629075 | Benign prostatic hyperplasia | |
| 126290751 | 12629075 | Blood glucose abnormal | |
| 126290751 | 12629075 | Chronic kidney disease | |
| 126290751 | 12629075 | Cough | |
| 126290751 | 12629075 | Decreased appetite | |
| 126290751 | 12629075 | Depression | |
| 126290751 | 12629075 | Fatigue | |
| 126290751 | 12629075 | Hyperlipidaemia | |
| 126290751 | 12629075 | Hypertension | |
| 126290751 | 12629075 | Hypophagia | |
| 126290751 | 12629075 | Metastases to bone | |
| 126290751 | 12629075 | Muscular weakness | |
| 126290751 | 12629075 | Nuclear magnetic resonance imaging abnormal | |
| 126290751 | 12629075 | Osteoarthritis | |
| 126290751 | 12629075 | Pain in extremity | |
| 126290751 | 12629075 | Tenderness | |
| 126290751 | 12629075 | Type 2 diabetes mellitus | |
| 126290751 | 12629075 | Varicella |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126290751 | 12629075 | 1 | 20160706 | 0 |